

EDITORIAL

The Rising Global Burden of Hemoglobinopathies, A Challenge and an Opportunity for Health Care in Pakistan

Lawrence Faulkner

Medical Coordinator, Cure2Children Foundation, Florence, Italy

Severe hemoglobinopathies, namely thalassemia major and sickle cell disease, are the most frequent life-threatening non-communicable disease of children globally: A minimum estimate of 300.000 newborns yearly have some symptomatic globin disorder, these births occur largely in low- and middle-income countries (LMICs) where prevention and management programs are often lacking or insufficient^{1,2}.

Hematopoietic stem cell transplantation, also known as blood or marrow transplantation (BMT), is the only established curative modality with success rates over 85% in low risk children with a compatible sibling³⁻⁵, moreover, BMT can normalize long-term health-related quality of life (HRQoL)^{6,7} and be highly cost effective^{8,9}. However, there is a dire shortage of BMT centers in hemoglobinopathy-prone regions¹⁰ which often fall in the low- and middle-income country (LMIC) strata, so that many families have to migrate to affluent countries seeking cure for their beloved ones; this not only aggravates misery, psychological and economical burden but perpetuates the hemorrhage of professional and financial resources to high-income countries (HIC).

Within structured collaboration programs low-risk matched-related BMT can be associated with very good results even in startup centers directly in LMICs^{11,12} and thus may provide a unique opportunity for saving lives, improve HRQoL, decrease financial burden of disease and promote capacity-building, research & development, and health care strengthening¹³.

BMT indications and outcomes: HICs vs. LMICs: The spectrum of BMT indications and procedures differ

between West and East¹⁰: in North America and Europe hematological malignancies are the most frequent indication and unrelated donors are often employed because of small average family size. In the Middle East and Asia non-malignant disorders, e.g. hemoglobinopathies and aplastic anemia, tend to be most common indications and matched related donors more frequently available¹⁴⁻¹⁶. Moreover, in addition to financial and logistic issues, the very limited use of unrelated volunteer donors in the East is also due to the fact that non-malignant disorders require stringent HLA matching and non-Caucasian ethnicities are generally underrepresented in donor registries¹⁷. Lastly, results using partially matched family donors for so called haploidentical transplantation, typically the mother or father, are increasingly encouraging¹⁸.

There is no evidence that, at least for low-risk matched related BMTs, outcomes are substantially different in HICs compared to LMICs. Glibel et al. assessed the impact of Human Development Index (HDI) on BMT results in adults with acute leukemia and found that transplantations performed in countries with an upper HDI were associated with improved leukemia-free survival, this however was not due to higher transplant-related mortality (TRM) but rather to higher relapse rates in LMICs, suggesting that the survival differences were probably related to patient selection and residual disease assessment rather than the BMT procedure itself¹⁹, and thus may not apply to non-malignant disorders.

In the experience of the Cure2Children Foundation (C2C) in supporting the startup of centers in Pakistan and India performing primarily low-risk matched-related BMTs for severe thalassemia aided by a structured peer to peer collaborative platform²⁰, outcomes where comparable to those obtained in Western centers²¹. There is also no

Address of Correspondence:

Lawrence Faulkner

Email: lawrence.faulkner@cure2children.org

evidence that in LMICs the spectrum of transplant-related infections is substantially different compared to the West^{22,23}.

Cost issues

BMT is one of the most expensive tertiary care procedures with costs generally above 150,000 USD in HICs²⁴. Figure 1 compares the relative cost breakdown of BMT for adult leukemia in HICs to the one for childhood thalassemia in LMICs underlining several interesting points: a) the major difference is related to follow up costs, probably because chronic GVHD is far more common, and to some extent therapeutically desirable, in adult leukemia; b) the second major difference is in hospitalization charges, which are related mostly to differences in salaries but also to BMT units construction and maintenance, in fact, complex infection control environments may not be needed for low-risk matched-related BMT in children with non-malignant diseases who arrive to transplant with no prior exposure to chemotherapy, no previous prolonged neutropenia episodes, no infections and in good general conditions¹²; c) diagnostics are also much less expensive in BMT for thalassemia since, for example, residual leukemia quantification or frequent chimerism analysis post BMT are not an absolute requirement as long as transfusion-independency is achieved; d) drugs and transfusion support is also different because of patient size and complication frequency, particularly fungal infections, the treatment of which may substantially impact on final costs. In fact, in the C2C experience in Pakistan and India the incidence of possible, probable or proven fungal infections²⁵ in young thalassemic children undergoing matched-related BMT is less than 2%²³. Within an existing hospital facility, less than 100,000 USD where sufficient to renovate and fully equip a 4-bed start up BMT unit²⁶. Increasing evidence suggest that complex and costly infection control environments may not be required²⁷⁻²⁹ and established international guidelines do not call for stringent air control systems, at least for low-risk BMTs³⁰.

The cure of severe hemoglobinopathies as a capacity-building opportunity

Optimal supportive care is often not available or not accessible in LMICs so that most children with severe hemoglobinopathies do not survive beyond 20 years of

age and the risk of blood-borne infections, primarily hepatitis C, is still substantial³².




Figure 1. Cost breakdown comparison of matched-related BMT in HIC (adult leukemia²⁴) and LMIC (children with thalassemia³¹); total cost \$116,000* and \$11,200 respectively (family support program not included)

As paradoxical as it may seem, BMT may actually be the best option for many patients with thalassemia in developing countries: It is a one-time procedure not depending on long-term access to appropriate medical care and at the same time greatly improves the quality of life for both patients and families by decreasing medical, psychological and financial burdens^{6,7}.

Buccal swab-based HLA-typing technology has greatly facilitated centralized compatibility testing so that there is no need to set up HLA laboratories locally, and patients can be easily typed worldwide and referred to BMT centers within South-South cooperation programs offering effective and cost-conscious BMT³³.

In the C2C-supported BMT network in Pakistan and India hinging on focused training and intensive online cooperation, low-risk matched-related BMT in children younger than 15 years is currently delivered with more than 95% thalassemia-free survival, a result at least as good as that obtained in HIC³, for an average cost of 12,000 USD per BMT^{4,31}. The realistic prospect of a definitive cure also improved compliance with supportive care and engaged families in cascade screening and prevention programs, e.g. most mothers of thalassemic children accepted the offer of free prenatal diagnosis for subsequent pregnancies.

Because of large patient loads, there is great potential for expertise on specific disease curable by BMT, for

example, Pakistan has at least 100 times the incidence of thalassemia compared to the West, and many cases have a compatible sibling donor due to large family size. As a result, many more transplants for young thalassemic children with a compatible donor are currently carried out in LMICs compared to Europe or North America³⁴. However, to take advantage of this opportunity, increasing efforts will have to focus on quality assurance platforms²⁰ and outcome reporting programs as a means of reassuring national and international patients, patient advocates, insurances and other sponsoring bodies. It seems reasonable to assume that if quality standards are assured, expertise is higher and costs are much lower, there might be the potential for patient attraction. Why should an insurance or national health system refuse to cover a patient willing, for example, to go from the UK to Pakistan in centers that have much more experience on specific diseases, e.g. Thalassemia, where appropriate quality standards are assured, outcome reporting is transparent and BMT costs are much less.

BMT for thalassemia offers several advantages for startup centers in LMICs: a) it is the least expensive and simplest form of allogeneic BMT with relatively basic technology requirements; b) being a chronic disease there is enough time to adequately prepare patients in order to maximize initial success rates; c) high commitment and compliance of affected families; d) children generally enjoy high cure rates and excellent HRQoL; e) high cost-effectiveness; f) potential for leading expertise and patient attraction.

Conclusion

BMT consists of a wide array of procedures which have very different complexities, outcomes and costs. The one used to cure young children with severe hemoglobinopathies having a compatible sibling sits on the simplest side of this spectrum, it's far less expensive than long-term supportive care and can restore a normal quality of life in most patients. It does not require complex hospital environments or undue sophisticated technologies. It can save the life of many children while being a great opportunity for health care strengthening, professional motivation and higher medical education. BMT may have positive ripple effects on institutions taking over the challenge as well as on screening and prevention programs in LMICs.

References

1. Modell, B. & Darlison, M. Global epidemiology of haemoglobin disorders and derived service indicators. (WHO website, 2009).
2. Weatherall, D. J. The inherited diseases of hemoglobin are an emerging global health burden. *Blood* 115, 4331–4336 (2010).
3. Angelucci, E. Hematopoietic Stem Cell Transplantation in Thalassemia. *Hematology* 456–462 (2010). doi:10.1182/asheducation-2010.1.456
4. Mehta, P. A. & Faulkner, L. B. Hematopoietic Cell Transplantation for Thalassemia: A Global Perspective. *Biol. Blood Marrow Transplant.* 19(1 Suppl), S70-3 (2013).
5. Bernaudin, F. et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. *Blood* 110, 2749–2756 (2007).
6. Cheuk, D. K. L. et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. *Bone Marrow Transplant.* 42, 319–327 (2008).
7. La Nasa, G. et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. *Blood* 122, 2262–2270 (2013).
8. Leelahavarong, P. et al. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. *BMC Health Serv Res* 10, 209–221 (2010).
9. Ho, W.-L. et al. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. *Bone Marrow Transplant* 37, 569–574 (2006).
10. Gratwohl, A. et al. Hematopoietic stem cell transplantation: a global perspective. *JAMA* 303, 1617–1624 (2010).
11. Faulkner, L. B., Uderzo, C. & Masera, G. International cooperation for the cure and prevention of severe hemoglobinopathies. *J. Pediatr. Hematol. Oncol.* 35, 419–423 (2013).
12. Faulkner, L. et al. ATG vs. thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. *Blood Advances* 1, 792–801 (2017).
13. Faulkner, L. Setting up Bone Marrow Transplantation for children with thalassemia may facilitate pediatric cancer care. *South Asian Journal of Cancer* 2, 109–112 (2013).

14. Hajeer, A. H., Algattan, M., Anizi, A., Alaskar, A. S. & Jarrar, M. S. Chances of finding a matched parent-child in hematopoietic stem cell transplantation in Saudi Arabia. *Am J Blood Res* 2, 201–202 (2012).
15. Klein, T. et al. Extended family studies for the identification of allogeneic stem cell transplant donors in Jewish and Arabic patients in Israel. *Pediatric Transplantation* 9, 52–55 (2005).
16. Elbejrani, W. M., Abdel-Rahman, F. & Ayad Ahmed Hussein. Probability of finding an HLA-matched donor in immediate and extended families: the Jordanian experience. *Biol. Blood Marrow Transplant.* 19, 221–226 (2013).
17. Switzer, G. E. et al. Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. *Blood* 121, 1469–1476 (2013).
18. Anurathapan, U. et al. Hematopoietic stem cell transplantation for homozygous β -thalassemia and β -thalassemia/hemoglobin E patients from haploidentical donors. *Bone Marrow Transplant* 51, 813–818 (2016).
19. Giebel, S. et al. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. *Blood* 116, 122–128 (2010).
20. Agarwal, R. K. et al. A prospective international cooperative information technology platform built using open-source tools for improving the access to and safety of bone marrow transplantation in low- and middle-income countries. *J Am Medical Informatics Association* In press, (2014).
21. Hussein, M. H. et al. Bone marrow transplantation for thalassemia: a global perspective. *Thalassemia Reports* 3, 103–107 (2013).
22. George, B., Mathews, V., Viswabandya, A., Srivastava, A. & Chandy, M. Infections in children undergoing allogeneic bone marrow transplantation in India. *Pediatr. Transplant* 10, 48–54 (2006).
23. Soni, R. et al. Infectious complications in 153 matched-related BMTs performed without HEPA filtration or positive pressure rooms in 3 BMT centres in South-East Asia. in 21st Asia-Pacific BMT meeting 285 (2016).
24. Blommestein, H. M. et al. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. *Ann. Hematol.* 91, 1945–1952 (2012).
25. Ascioglu, S. et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin. Infect. Dis.* 34, 7–14 (2002).
26. Ramprakash, S. et al. Low-cost matched sibling bone marrow transplant for standard-risk thalassemia in a limited-resource setting. *Pediatric Hematology Oncology Journal* 107–113 (2017). doi:10.1016/j.phoj.2017.12.002
27. Kumar, R. et al. Allogeneic hematopoietic SCT performed in non-HEPA filter rooms: initial experience from a single center in India. *Bone Marrow Transplant* 43, 115–119 (2009).
28. Solomon, S. R. et al. Outpatient myeloablative allo-SCT: a comprehensive approach yields decreased hospital utilization and low TRM. *Bone Marrow Transplantation* 45, 468–475 (2010).
29. Svahn, B.-M. et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. *Blood* 100, 4317–4324 (2002).
30. McGrath, E. International Standards for Cellular Therapy Product Collection, Processing and Administration Accreditation Manual, FACT-JACIE 6th edition. (2015).
31. Faulkner, L. et al. Transplantation in low resource countries. *Thalassemia Reports* 1, 30–33 (2011).
32. Di Marco, V. et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. *Blood* 116, 2875–2883 (2010).
33. Agarwal, R. K. et al. The Case for High Resolution Extended 6-Loci HLA Typing for Identifying Related Donors in the Indian Subcontinent. *Biology of Blood and Marrow Transplantation* 23, 1592–1596 (2017).
34. Sabloff, M. et al. HLA-matched sibling bone marrow transplantation for β -thalassemia major. *Blood* 117, 1745–1750 (2011).